TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07216105: FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Sponsor: Fate Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 119 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07216105 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07216105 Rescue Dossier →